What are the opening hours?

Monday 7am - 7pm Tuesday 7am - 7pm Wednesday 7am - 7pm Thursday 7am - 7pm Friday 7am - 7pm

Caris Life Sciences

Home
United States
Irving, TX
Caris Life Sciences

Caris Life Sciences delivers technologies to revolutionize healthcare with market-leading profiling

Caris Life Sciences® is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

01/01/2026

Happy New Year from everyone at Caris. We wish you a joyful 2026!

12/26/2025

Elevate precision care with liquid biopsy from Caris Assure, an innovative multi-cancer assay that provides deep molecular insights from a simple blood sample. Explore how this powerful liquid biopsy assay can revolutionize patient care. Learn more: https://ow.ly/Ohce50XNSha

12/23/2025

Wishing you and your family Happy Holidays from Caris Life Sciences.

12/19/2025

The Caris Precision Oncology Alliance welcomes Providence Swedish Cancer Institute and its focused translational research extension, the Paul G. Allen Research Center.

“We are proud to welcome the Providence Swedish Cancer Institute and the Paul G. Allen Research Center to the Caris Precision Oncology Alliance. They strive to provide patients with earlier access to promising therapies,” said James Hamrick, MD, MPH, Chairman of the Caris POA. “Their scale, expertise and commitment to research-driven care make them an ideal institution in our shared commitment to accelerate precision oncology and deliver better options and outcomes for patients.”

Learn more:
https://ow.ly/1Mm650XLLil

12/17/2025

MI Cancer Seek provides molecular profiling for solid tumors with FDA-approved CDx indications. Available for both adults & pediatric (ages 1-22) patients.

Learn more & view important product info: https://ow.ly/1PE950VCL53

12/16/2025

Today, Caris announced that its therapeutic research arm, Caris Discovery, has entered into a multi-year collaboration and license agreement with Genentech. In this collaboration, Caris will work to identify and validate novel oncology targets in solid tumor tissue.

"At Caris, we are committed to making precision medicine a reality for all patients. This innovative collaboration with Genentech is specifically designed to identify and validate novel targets in solid tumors. By combining Caris’ unparalleled multimodal data and tissue-based discovery engine with Genentech’s deep expertise in therapeutics development, we hope to enable the development of first-in-class medicines for cancer patients,” said Milan Radovich, PhD, Senior Vice President and Chief Scientific Officer at Caris.

Learn more: https://ow.ly/Ij0N50XK3wL

12/12/2025

Caris and collaborators within the Caris Precision Oncology Alliance (Caris POA) collectively presented 19 studies across a range of breast cancer types at the San Antonio Breast Cancer Symposium (SABCS). Here’s a glimpse at a few of the presentations.

12/11/2025

is underway. Stop by Booth 209 to meet with the Caris Life Sciences team and explore how our molecular profiling and AI-driven insights are shaping the future of oncology. We’re ready to connect: https://bit.ly/4ovX0tz

12/10/2025

Today during , researchers presented the initial findings from a major multi-year collaboration between the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Caris Life Sciences® (Caris) focused on transforming recurrence risk assessment in early-stage breast cancer through artificial intelligence (AI).

“By integrating imaging, clinical data, and molecular profiling, we are advancing beyond single-dimension diagnostics to deliver a more precise and comprehensive understanding of recurrence risk in breast cancer,” said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD.

Learn more: https://ow.ly/vzQ450XHb3F

12/08/2025

Join Caris at the San Antonio Breast Cancer Symposium to explore the next era of cancer diagnostics. Stop by booth 209 to meet our team and discover how our advanced molecular profiling solutions are helping redefine cancer care. https://bit.ly/4ovX0tz

12/04/2025

Caris and collaborators within the Caris Precision Oncology Alliance (Caris POA) will collectively present 19 studies across a range of breast cancer types at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025.

“SABCS is the premier global stage for advancing breast cancer research, and we are excited to share how Caris’ multiomic tumor profiling is helping define molecularly distinct patient groups,” said George W. Sledge, Jr., MD, Caris EVP and Chief Medical Officer.

Learn more: https://ow.ly/JfWr50XBChl

12/03/2025

Join Caris Life Sciences at ASH 2025 in Orlando. We're excited to connect with oncology leaders and share how our precision medicine innovations are advancing cancer care. Visit us at Booth 281. Learn more: https://ow.ly/zZjp50XBnbf

Address

-
Irving, TX
75039

Opening Hours

Monday	7am - 7pm
Tuesday	7am - 7pm
Wednesday	7am - 7pm
Thursday	7am - 7pm
Friday	7am - 7pm

Telephone

+18889798669

Website

https://www.carislifesciences.com/

Alerts

Be the first to know and let us send you an email when Caris Life Sciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Psych Dimensions

Want your practice to be the top-listed Clinic in Irving?

#WeAreCarisLS

We believe in more treatment options. Because more treatment options, can mean more time with the ones you love the most.

We’re dedicated to fulfilling the promise of precision medicine and changing the face of cancer care by providing the personalized and precise information needed to guide individualized treatment options. Learn more about our suite of market-leading molecular profiling offerings that assesses DNA, RNA and proteins to reveal the highest quality molecular blueprint so you can determine treatment options with confidence: www.carismolecularintelligence.com.